SCHEMBL18170040

SCHEMBL18170040

Nc1cnn(COP(=O)(O)O)c1

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
ALDH1A1 P00352 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HIF1A Q16665 1/20 0.34
PNP P00491 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18169984 0.79
SCHEMBL18169860 0.79
SCHEMBL18176879 0.79 ALPI (0.39) LMNAALDH1A1KMT2A
SCHEMBL20191322 0.77 S1PR1 (0.34) MAPTL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL18170086 0.73
SCHEMBL10200595 0.72
SCHEMBL20415636 0.70 S1PR1 (0.32)
SCHEMBL18170087 0.69 GAA (0.31)
SCHEMBL17508623 0.69 MEN1 (0.42) MAPTLMNAL3MBTL1ALDH1A1PKM
SCHEMBL673074 0.67 MAPT (0.42) MAPTLMNAL3MBTL1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289776-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2022-09-15 US disclosed
US-11370808-B2 Pyrazole compounds and methods for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2022-06-28 US disclosed
EP-3286181-B1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS INC (US) 2021-01-27 EP disclosed
US-20190153006-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2019-05-23 US disclosed
US-10208075-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2019-02-19 US disclosed
US-10208074-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2019-02-19 US disclosed
US-20180208613-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
US-20180208612-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
US-9982000-B2 Pyrazole compounds and method for making and using the compounds RIGEL PHARMACEUTICALS, INC. (US) 2018-05-29 US disclosed
EP-3286181-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS Rigel Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016172560-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
US-20160311839-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370808-B2 Pyrazole compounds and methods for making and using the compounds IRAK3, IRAK1, IRAK2 MAPT 2941/4885LMNA 2091/4885L3MBTL1 1988/4885
US-10208074-B2 Pyrazole compounds and method for making and using the compounds IRAK3, IRAK1, IRAK2 MAPT 2923/4885LMNA 2059/4885L3MBTL1 2166/4885
US-20190153006-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 MAPT 2941/4885LMNA 2091/4885L3MBTL1 1988/4885
US-20180208613-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 MAPT 2923/4885LMNA 2059/4885L3MBTL1 2166/4885
US-10208075-B2 Pyrazole compounds and method for making and using the compounds IRAK3, IRAK1, IRAK2 MAPT 2923/4885LMNA 2059/4885L3MBTL1 2166/4885
US-20180208612-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 MAPT 2923/4885LMNA 2059/4885L3MBTL1 2166/4885
US-20160311839-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 MAPT 2923/4885LMNA 2059/4885L3MBTL1 2166/4885
US-20220289776-A1 PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 MAPT 2941/4885LMNA 2091/4885L3MBTL1 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.